



March 2, 2017

Aquinox Pharmaceuticals to Announce 2016 Year End Financial Results

- Conference call Thursday, March 9, 2017 at 4:30PM ET -

VANCOUVER, British Columbia, March 02, 2017 (GLOBE NEWSWIRE) -- [Aquinox Pharmaceuticals, Inc.](#) ("[Aquinox](#)") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, will report its financial results for the year ending December 31, 2016 and will provide a general business update on Thursday, March 9, 2017 after U.S. financial markets close. [Aquinox](#) will host a conference call and live audio webcast on Thursday, March 9th, 2017 at 4:30 PM (ET) / 1:30 PM (PT).

Conference Call and Webcast Details:

Date: Thursday, March 9th, 2017

Time: 4:30 PM (ET) / 1:30 PM (PT)

Toll-free: (866) 357-7878

International: (315) 625-3088

Conference ID: 72144360

Webcast URL: <http://edge.media-server.com/m/p/askid88w>

The live webcast may be accessed through the "[Events & Presentations](#)" page in the "[Investor Relations](#)" section of the company's website at www.aqxpharma.com.

The archived webcast will also be available on [Aquinox](#)'s website approximately two hours after the event and will be available for replay for at least 30 days after the event.

About [Aquinox Pharmaceuticals, Inc.](#)

Aquinox Pharmaceuticals, Inc. is a late clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Our primary focus is anti-inflammatory product candidates targeting SH2-containing inositol-5'-phosphatase 1, or SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. Aquinox's lead drug candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. In September 2016, we began enrolling patients in a Phase 3 clinical trial of AQX-1125 in our lead indication, Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS). Other indications are under consideration for future investigation. Aquinox has a broad intellectual property portfolio and pipeline of preclinical drug candidates that activate SHIP1. For more information, please visit www.aqxpharma.com.

Investor Contact Info:

Brendan Payne

Associate Director, Investor Relations

[Aquinox Pharmaceuticals, Inc.](#)

604.901.3019

ir@aqxpharma.com

Gitanjali Ogawa

Vice President

[The Trout Group](#)

646-378-2949

Gogawa@troutgroup.com

Source: Aquinox Pharmaceuticals, Inc.

News Provided by Acquire Media